Morgan Stanley Issues Pessimistic Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price

BridgeBio Pharma (NASDAQ:BBIO) had its price objective cut by equities research analysts at Morgan Stanley from $98.00 to $97.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price target points to a potential upside of 15.59% from the stock’s previous close.

Several other equities analysts have also recently weighed in on the company. Mizuho dropped their price objective on BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating for the company in a report on Tuesday, June 16th. Truist Financial raised their price target on BridgeBio Pharma from $95.00 to $102.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of BridgeBio Pharma in a research report on Friday, May 15th. Raymond James Financial downgraded shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 26th. Finally, HC Wainwright raised their target price on shares of BridgeBio Pharma from $110.00 to $120.00 and gave the company a “buy” rating in a report on Monday, July 13th. Nineteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $99.28.

BridgeBio Pharma Trading Down 0.9%

Shares of NASDAQ:BBIO traded down $0.76 during trading on Tuesday, hitting $83.92. 990,910 shares of the company were exchanged, compared to its average volume of 2,991,225. BridgeBio Pharma has a fifty-two week low of $46.81 and a fifty-two week high of $93.42. The stock has a market cap of $16.40 billion, a price-to-earnings ratio of -22.45 and a beta of 0.96. The firm has a fifty day moving average price of $76.07 and a two-hundred day moving average price of $73.03.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The company had revenue of $243.68 million during the quarter, compared to analyst estimates of $220.91 million. The business’s revenue for the quarter was up 120.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.95) EPS. As a group, research analysts predict that BridgeBio Pharma will post -2.31 EPS for the current year.

Insider Activity at BridgeBio Pharma

In related news, Director Randal W. Scott sold 10,000 shares of BridgeBio Pharma stock in a transaction on Friday, May 15th. The shares were sold at an average price of $67.15, for a total value of $671,500.00. Following the completion of the sale, the director owned 11,589 shares of the company’s stock, valued at approximately $778,201.35. This trade represents a 46.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Andrea Ellis sold 17,167 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $84.00, for a total value of $1,442,028.00. Following the completion of the sale, the director directly owned 22,579 shares of the company’s stock, valued at $1,896,636. The trade was a 43.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 392,117 shares of company stock worth $29,934,700. 14.23% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BridgeBio Pharma

Institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC boosted its stake in shares of BridgeBio Pharma by 19.8% in the 1st quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock valued at $978,608,000 after purchasing an additional 2,178,556 shares in the last quarter. Farallon Capital Management LLC raised its holdings in shares of BridgeBio Pharma by 9.8% during the fourth quarter. Farallon Capital Management LLC now owns 8,998,463 shares of the company’s stock valued at $688,292,000 after acquiring an additional 806,463 shares in the last quarter. Invesco Ltd. increased its position in shares of BridgeBio Pharma by 23.0% during the fourth quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock valued at $369,547,000 after buying an additional 902,648 shares during the period. Geode Capital Management LLC raised its position in shares of BridgeBio Pharma by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 4,412,523 shares of the company’s stock worth $344,689,000 after acquiring an additional 502,582 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in BridgeBio Pharma by 144.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company’s stock valued at $292,862,000 after acquiring an additional 2,261,181 shares during the period. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma News Roundup

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Analysts raise targets: Piper Sandler increased its price target from $111 to $115 and maintained an “overweight” rating. Wells Fargo also raised its target, from $98 to $102, while keeping an “overweight” rating. The revisions imply substantial potential upside and reflect continued confidence in BridgeBio’s development pipeline. Benzinga analyst price-target updates
• Positive Sentiment: Pipeline catalysts could drive sentiment: BridgeBio is listed among biotech companies with major second-half 2026 catalysts, including potential regulatory decisions and late-stage clinical-trial readouts. Positive data or approvals could provide important valuation catalysts for BBIO. 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
• Neutral Sentiment: Revenue growth was strong: Second-quarter revenue reached $243.7 million, beating the $220.9 million consensus estimate and increasing 120.4% from the prior year. The improvement suggests commercial and partnered-product activity is expanding, although investors remain focused on the company’s path toward profitability. BridgeBio Pharma Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Quarterly loss exceeded expectations: BridgeBio reported a second-quarter loss of $0.78 per share, wider than the $0.58 analyst consensus, despite improving from a $0.95 loss per share a year earlier. The earnings miss may limit the stock’s near-term upside and reinforce concerns about ongoing cash needs and operating costs. BridgeBio Pharma Q2 Earnings Results and Conference Call

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.